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Abstract
Background: The purpose of our study is to examine the long (5-year) efficacy of the all surface laser
ablation (ASLA) combined with accelerated cross-linking (CXL) for the treatment of myopia without the use of
mitomycin-C (MMC).
Methods: This retrospective study consisted of 202 eyes of 118 myopic (SD: 2.41, range: − 1.50 to − 12.75 D)
patients (44 males, 74 females). Mean age was 28.50 years (SD: 6.45, range: 18 to 51 years) that underwent
ASLA with accelerated CXL for the treatment of their myopia.
Results: The patients underwent routine postoperative assessment on the 1st, 3rd, 7th day and in the 1st,
3rd, 6th and 12th month, 30th month (±6 months), 4th and 5th year. The mean spherical equivalent (SEq)
refractive error changed from − 6.41 ± 2.41 D preoperatively to − 0.02 ± 0.53 D at 5 years postoperatively. The
haze score was 0.18, 0.25 and 0.28 at 1, 3 and 6 months postoperatively. At 12 months after the treatment, no
eyes had significant corneal haze and in all the following postoperative time intervals the haze traces were
gone.
Conclusion: ASLA combined with accelerated CXL (ASLA-XTRA) appears to be safe, efficacious and offering
very good refractive results. The potential additional benefits of this modality are the stabilizing effect of the
refraction and its sterilization effect on the treated cornea without the potential side effects of MMC.
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Introduction
Photorefractive keratectomy (PRK) is a well-known pro-
cedure for the correction of myopia by ablating the sur-
face of the cornea after removing the epithelium by
mechanical or chemical debridement. The primary issue
following surface ablation methods is the incidence of
postoperative corneal haze because of the wound healing
process after the treatment, as it may lead to a substan-
tial decrease of visual acuity and may possibly necessitate
further interventions in order to enhance the patient’s
vision. However, the introduction of mitomycin-C
(MMC) was a significant step in the re-evaluation of sur-
face ablation techniques as it has been proven to have a
positive effect on the prevention of postoperative corneal
haze formation [1–3].
A similar method named tPRK (PTK-PRK) consists of
initial laser epithelial removal with PTK – usually using
a flat rather than refractive neutral profile – followed by
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a PRK treatment at a second distinct step, is also well
described [4–11].
However, in recent years, a modified excimer laser
trans-epithelial surface ablation technique was intro-
duced by Schwind eye-tech-solutions, Germany) [7,
10, 12, 13]. This technique, although different in
mechanism, was named also, inappropriately in our
opinion, Trans-PRK. More specifically, in this tech-
nique, the whole treatment is performed in one step
combining both epithelium and stromal ablation in a
single-step ablation profile. In this modality, unlike
tPRK, the epithelium is removed by the excimer laser
based on customized epithelial thickness profile [14–
16] in a way that assures refractive neutrality. The
other difference is that the refractive component of
the treatment profile is initially applied on the cornea
followed by the epithelial one [7]. Therefore, in order
to avoid any kind of confusion when referring to
Schwind’s Trans-PRK, we have introduced and been
using the term all surface laser ablation (ASLA) in all
our previous studies [7, 17–19].
The well-established PTK and PRK treatments have
also both been studied before in combination with
corneal cross-linking (CXL) procedures in order to
improve stability and reduce the refractive error in
cases of ectasia, such as keratoconus. In this setting,
CXL acted as a stabilizing intervention on the degen-
erated cornea [19–21]. It has been demonstrated [22,
23] that, after the CXL treatment, once the epithelial
defect has fully healed, there is transformation and
then apoptosis of the myofibroblasts, followed by sub-
sequent repopulation by new keratocytes, and re-
absorption of the myofibroblast derived abnormal
collagen depositions and cell debris, this process en-
hancing corneal clarity.
We hypothesized that this cellular process induced
by CXL may have a beneficial effect on reducing sub-
epithelial haze following ASLA transepithelial PRK.
The aim of this research study was to investigate the
5-year efficacy, the effectiveness in preventing haze
formation and the safety of the previously described
ASLA-XTRA [18] modality which consists of ASLA
followed by accelerated CXL for the treatment of pa-
tients with moderate to high myopia avoiding MMC
and its potential side effects (e.g., corneal melting,
endothelial cell loss) [24].
Materials and methods
This study was performed at Emmetropia Eye Insti-
tute in Greece. To be included in this retrospective
study, all patients had to be 18 years old or more
with myopic spherical equivalent (SEq) refraction
stable for more than 1 year. Patients with ocular co-
pathology or previous surgery, inflammatory or
infectious corneal disease, systemic diseases (with ocular
involvement) and keratoconus were excluded. Three
weeks prior to surgery, patients discontinued wearing con-
tact lenses. All participants were informed before their
participation in the study as well as the risks and the ad-
vantages of the surgery and signed a written paper before
the treatment. The study was conducted following the
principles of the Declaration of Helsinki and ethical ap-
proval was provided by the Emmetropia’s institutional re-
view board.
Preoperative assessment
The preoperative assessment included uncorrected
(UDVA) and corrected (CDVA) distant visual acuity,
non-cycloplegic and cycloplegic manifest refraction,
and slit lamp examination, including dilated fundos-
copy and measurement of intraocular pressure (ICare,
ic100, ICare Finland, Oy, Finland). The preoperative
assessment also included corneal topography using
Orbscan IIz (Bausch and Lomb, Rochester, NY, USA).
Pachymetric and epithelial thickness measurements
were performed using Optovue OCT (Optovue, Fre-
ment, CA, USA).
Surgical technique
The treatments were performed using the Schwind
AMARIS 750S excimer laser platform and had
aberration-free (aspheric) profiles.
Patients were given 1.5 mg bromazepam (Lexotanil,
Roche Hellas Α.Ε.) preoperatively and one drop of
proparacaine (Alcaine, Alcon, USA) was instilled three
times 15 min before surgery. Povidone iodine 5% solu-
tion (Betadine) was applied on the eyes prior to the
application of an upper lid drape and of a speculum.
Wet sponge application (three slow, painting move-
ments on the corneal surface) was performed using a
Merocel® sponge (Medtronic Inc., Minneapolis, MN,
USA) dipped in balanced salt solution (BSS) in order
to avoid uneven wetting and, therefore, uneven abla-
tion. After the ASLA treatment was performed, the
cornea was chilled with 20 mL of low temperature
BSS (4 °C). Following ASLA, an accelerated CXL
treatment was performed using the Avedro KXL sys-
tem (Avedro Inc., Waltham, MA). The riboflavin solu-
tion used was Vibex Rapid (Avedro Inc., Waltham,
MA), the formulation of which is: 0.1% riboflavin, Sa-
line, HPMC. The soaking time before the UV irradi-
ation was 90s and the energy used 2.7 J/cm2 (30 mW
for 90 s). Finally, a drop of Ofloxacin 0.3% (Exocin,
Allergan Inc., Irvine, CA, USA) was applied and a
bandage contact lens (Acuvue Oasys; Johnson &
Johnson, Jacksonville, FL, USA). After surgery, topical
Ofloxacin 0.3% (Exocin, Allergan Inc., Irvine, CA,
USA) was applied four times per day until complete
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epithelial closure and removal of the contact lens.
Dexamethasone 0.1% eye drops (Maxidex, Novartis,
Basel, Switzerland) qid were used for 1–2 weeks, re-
placed with fluorometholone alcohol 0.1% (FML,
Allergan Inc., Irvine, CA, USA) for 10 weeks, and arti-
ficial tears for 3 months (Thealoz Duo Eye Drops;
Laboratoires Thea, France) were prescribed.
Treatment parameters
The average maximum ablation depth was 150.65 μm
(SD: 29.96, range 81.17 to 226.78 μm). This also includes
the epithelium according to the epithelial profile used by
Schwind (55 μm centrally). As a result, the average stro-
mal ablation depth was 95.65 μm (range 26.17 to
171.78 μm) while the residual stromal thickness was
385.56 μm (SD: 40.27, range 316.26 to 500.39 μm). The
mean optical zone was 6.29 mm (SD: 0.26, range 5.7 to
7 mm). In all cases, the choice of the optical zone was
made following the manufacturer’s guidelines taking also
into consideration the amount of the tissue what would
be ablated in each case, the pupil size and the pachy-
metric values of each patient. As a result, the optical
zone was reduced, compared to the manufacturer’s sug-
gestions, in some cases. The CXL energy used was 2.7 J/
cm2. There were no intraoperative complications during
the treatments.
Postoperative follow up
Patients underwent routine postoperative assessment on
the 1st, 3rd, 7th day and in the 1st, 3rd, 6th and 12th
month, 30th month (±6 months), 4th and 5th year. Dur-
ing the postoperative period from 1month onwards,
subjective refraction, slit lamp biomicroscopy, intraocu-
lar pressure measurement were performed. The corneal
haze was graded with an ordinal scale described by
Fantes et al. [25]
Results
Two hundred and two eyes (99 right and 103 left
eyes) of 118 patients meeting the inclusion criteria
were included. There were 44 male and 74 female pa-
tients. Mean age was 28.5 years (SD: 6.45, range 18 to
51). The mean pachymetry value and Kmax values
before the treatment were 536.21 μm (SD: 42.80,
range 434 to 650) and 45.06 D (SD: 1.71, range 40.5
to 50.1), respectively. The epithelium had a mean
value of 54.94 μm (SD: 1.04, range 52 to 58). Mean
preoperative SEq refractive error was − 6.41 D (SD:
2.41, range − 1.5 to − 12.75).
Mean pre-operative CDVA was 0.018 logMAR (SD:
0.069, range 0.3 to − 0.2) and the mean pre-operative
UDVA was 2.745 logMAR (SD: 0.68, range 3 to 0.54).
At 12 months post-operatively (113 eyes), the SEq was
− 0.08 D (SD: 0.36, range − 1.50 to 0.625). Mean CDVA
at 12 months was 0.008 logMAR (SD: 0.69 range 0.3 to
− 0.1) and the mean UDVA at the same period was
0.03 logMAR (SD: 0.09, range 0.4 to − 0.1).
At 30 ± 6months post-operatively (90 eyes), the SEq
was − 0.23 D (SD: 0.43, range − 1.50 to 0). Mean CDVA
at 30 ± 6months was 0.008 logMAR (SD: 0.05 range 0.18
to − 0.1) and the mean UDVA at the same period was
0.04 logMAR (SD: 0.07, range 0.18 to − 0.1).
At 4 years post-operatively (83 eyes), the SEq was − 0.14
D (SD: 0.38, range − 1.375 to 0.25). Mean CDVA at 4 years
was 0.003 logMAR (SD: 0.04 range 0.2 to − 0.1) and the
mean UDVA at the same period was 0.05 logMAR (SD:
0.1, range 0.3 to − 0.1).
At 5 years post-operatively (72 eyes), the SEq was − 0.02
D (SD: 0.53, range − 1.625 to 1.5). Mean CDVA at 5 years
was 0.007 logMAR (SD: 0.05 range 0.2 to − 0.1) and the
mean UDVA at the same period was 0.064 logMAR (SD
0.18, range 1 to − 0.1) (Fig. 1).
Regarding haze, the haze score was 0.18, 0.25 and 0.28
at 1, 3 and 6months postoperatively. At 12 months after
the treatment, no eyes had significant corneal haze (only
insignificant haze traces were present in a few eyes). In
all the following postoperative time intervals the haze
traces were gone (Fig. 2).
Discussion
In this study we elaborate on our recent publication
[18], a comparative study suggesting the use of acceler-
ated CXL instead of MMC for the prevention of postop-
erative corneal haze formation, by reporting the long
term outcomes of ASLA-XTRA. We used a total energy
of 2.7 J/cm2 which is half the energy delivered during
conventional CXL following the Dresden protocol. The
main goal of this accelerated, superficial fluence is to
maintain the corneal strength without inducing a re-
fractive change. The results of the current study seem to
corroborate the results of the original study comparing
ASLA with MMC vs. ASLA-XTRA. The refractive out-
come is stable 5 years after the treatment with good re-
sults in terms of UDVA, there was no loss of 2 or more
lines of BCVA in any case, and the postoperative refrac-
tion that are very similar to the existing literature. There
were ~ 3–4 eyes (patients older than 50 years old) that
lost one line of BCVA but that loss has occurred merely
due to lenticular changes and not because of corneal
pathology.
According to our long-term dataset, the ASLA-XTRA
technique seems to have very encouraging results in
terms of preventing corneal haze formation while main-
taining good efficacy and stability. The only haze forma-
tion that was observed was from the 1st and until the
6th month postoperatively and we speculate that it was
caused also by the CXL procedure itself and, in any case,
did not affect the patients’ vision significantly. Lastly,
Aslanides et al. Eye and Vision            (2020) 7:31 Page 3 of 6
Fig. 1 ASLA-XTRA long term results regarding the a) Efficacy of the method (postoperative UDVA vs. preoperative CDVA, b) Difference between
the UDVA and the CDVA (in Snellen Lines), c) Safety (change in CDVA), d) Achieved vs. attempted spherical equivalent refraction, e) Accuracy of
the spherical equivalent refraction, f) Stability of the spherical equivalent refraction and g) Amplitude of the astigmatism
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randomized blind comparative studies of MMC vs. CXL,
with larger sample size, concerning the safety, the effi-
cacy and the prevention of haze after PRK, are needed in
the future to corroborate our results.
Conclusions
We favor the use of CXL in place of MMC in refract-
ive laser ablation mainly because we believe that CXL
has similar MMC-like effect on fibroblast activity in
decreasing haze formation. In addition, it contributes
to the postoperative biomechanical stability of the
cornea and, as a result, a refraction that could poten-
tially be more stable in the long term. Finally, CXL
offers a cornea sterilizing effect, thanks to the com-
bination of riboflavin and UV radiation, and conse-
quently may reduce the possibility of postoperative
infections.
Overall, our long-term data have comparable inci-
dence of haze to published incidence with the use of
MMC [2, 17, 18, 26]. This suggests that both the top-
ical application of MMC 0.02% and accelerated CXL,
by having the same effect on the corneal fibroblasts,
are equally effective in preventing the long-term de-
velopment of post-operative corneal haze, with
equivalent refractive results, in moderate to high my-
opic patients. In this regard it is worth noting that
the deep haze seen after conventional CXL differs
from the subepithelial haze after PRK, with the latter
being the target of this intervention. In this regard, it
is also noteworthy that unlike other studies suggesting
visually significant haze following combined excimer
ablation/ CXL, our protocol did not use a full 30 min
CXL treatment, but rather a highly accelerated and
reduced energy treatment, which may explain the lack
of deep stromal or visually significant haze in our
study [27]. Overall, the combination of stability, lack
of haze and sterilizing effect make ASLA-XTRA our
favorite methodology even though compared to
MMC, the CXL treatment is less cost-effective.
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